ArticleFrontiers in immunology2021
Zika Virus Envelope Domain III Recombinant Protein Delivered With Saponin-Based Nanoadjuvant From
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Purification, refolding, and pH-dependent stability evaluation of Zika virus EDIII protein.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Mouse strain-dependent neutralizing antibody responses to Zika virus vaccines.Journal of microbiology (Seoul, Korea) · 2025Article
- Leaf Saponins ofPharmaceutics · 2025Review
- Toll-like receptor response to Zika virus infection: progress toward infection control.Npj viruses · 2025Review
- A Lambda-evo (λApplied microbiology and biotechnology · 2025Article
- Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SAInternational journal of molecular sciences · 2024Article
- Intranasal Delivery ofVaccines · 2024Article
- Production of Recombinant Zika Virus Envelope Protein by Airlift Bioreactor as a New Subunit Vaccine Platform.International journal of molecular sciences · 2023Article
- Whole Yeast Vaccine Displaying ZIKV B and T Cell Epitopes Induces Cellular Immune Responses in the Murine Model.Pharmaceutics · 2023Article
- Article
- Article
- Vaccination with a Zika virus envelope domain III protein induces neutralizing antibodies and partial protection against Asian genotype in immunocompetent mice.Tropical medicine and health · 2022Article
- Current Advances in Zika Vaccine Development.Vaccines · 2022Review
- Zika Virus Envelope Protein Domain III Produced inDiagnostics (Basel, Switzerland) · 2022Article
- Structure Elucidation of Triterpenoid Saponins Found in an Immunoadjuvant Preparation ofMolecules (Basel, Switzerland) · 2022Article
- ISCOM-Matrices Nanoformulation Using the Raw Aqueous Extract ofBioNanoScience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoadjuvants that combine immunostimulatory properties and delivery systems reportedly bestow major improvements on the efficacy of recombinant, protein-based vaccines. Among these, self-assembled micellar formulations named ISCOMs (immune stimulating complexes) show a great ability to trigger powerful immunological responses against infectious pathogens. Here, a nanoadjuvant preparation, based on saponins from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.